Chronic Myeloid Leukemia Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight

DelveInsight's, "Chronic Myeloid Leukaemia Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the Chronic Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report
• On May 26, 2026- Novartis Pharmaceuticals initiated a study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
• On May 20, 2026- M.D. Anderson Cancer Center conducted a Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
• DelveInsight's Chronic Myeloid Leukemia pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Myeloid Leukemia treatment.
• The leading Chronic Myeloid Leukemia Companies such as Renascience, Novartis Pharmaceuticals, AOP Orphan Pharmaceuticals GmbH, ImmunoForge, Enliven Therapeutics, MacroGenics and others.
• Promising Chronic Myeloid Leukemia Pipeline Therapies such as Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.

Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Myeloid Leukemia Overview
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen. CML is a fairly slow growing leukemia, but it can change into a fast-growing acute myeloid leukemia that's hard to treat. CML does not usually cause any symptoms in its early stages and may only be picked up during tests carried out for another reason. As the condition develops, symptoms can include tiredness, weight loss, night sweats, tenderness and swelling in the left side of your tummy, feeling full after small meals, pale skin and shortness of breath and a high temperature.

Chronic Myeloid Leukemia Emerging Drugs Profile
• RS-5614: Renascience
RS‐5614 is an investigational therapy being developed by Renascience for the treatment of CML. RS5614 has passed all non-clinical safety tests required for clinical trials and manufacturing and sales as a drug. In addition, RS5614 has been administered to nearly 400 subjects (healthy people, chronic myeloid leukemia, novel coronavirus lung injury, malignant melanoma, lung cancer, systemic sclerosis, etc.), and long-term administration for one year was also performed for chronic myeloid leukemia, but no problematic side effects due to RS5614 have been reported, and it is considered to be a highly safe drug. In the past, many pharmaceutical companies and bio start-ups, both in Japan and overseas, have been working on developing small molecule PAI-1 inhibitors, and some of the drugs have been reported to be effective in animal models of mice and rats. However, all of these were discontinued at an early stage of development, and our drug is the oral PAI-1 inhibitor currently in the human clinical stage. Currently the drug is in Phase III stage of development for the treatment of CML.

• ABL001: Novartis Pharmaceuticals
ABL001 is an investigational targeted therapy developed by Novartis Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and other cancers. It is a small‐molecule allosteric inhibitor that specifically binds to the myristoyl pocket of the BCR‐ABL1 fusion protein, a key driver of CML. By targeting the BCR‐ABL1 oncoprotein through a distinct mechanism from traditional tyrosine kinase inhibitors, ABL001 aims to overcome resistance and improve disease control. The drug is being evaluated in clinical studies to assess its safety, tolerability, and efficacy in patients with CML, including those with resistant or refractory disease. Currently the drug is in Phase II stage of development for the treatment of CML.

• ELVN-001: Enliven Therapeutics
ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 targets the ATP-binding site of the ABL1 kinase domain and binds to a unique P-loop "folded-in" active conformation of ABL1, creating a narrow selectivity tunnel against the broader kinome. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR-ABL mutation, which confers resistance to nearly all approved tyrosine kinase inhibitors (TKIs), as well as activity against mutations known to confer resistance to allosteric BCR-ABL inhibitors. As per the company pipeline, the drug is in Phase I stage of its clinical trial for the treatment of Chronic Myeloid Leukemia.

• MGD024: MacroGenics
MGD024 is an investigational bispecific DART® molecule being developed by MacroGenics for the treatment of chronic myeloid leukemia (CML) and other hematologic malignancies. It simultaneously engages CD123 on leukemic cells and CD3 on T‐cells, directing cytotoxic T‐cell activity against malignant cells. By harnessing the immune system, MGD024 aims to eliminate leukemic cells more effectively than conventional therapies. The drug is currently in early‐stage clinical development, with studies evaluating its safety, tolerability, and anti‐leukemic activity in patients with CML and related disorders.

The Chronic Myeloid Leukemia Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myeloid Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia Treatment.
• Chronic Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myeloid Leukemia market

Stay informed about the Chronic Myeloid Leukemia pipeline trends! @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Myeloid Leukemia Companies
Renascience, Novartis Pharmaceuticals, AOP Orphan Pharmaceuticals GmbH, ImmunoForge, Enliven Therapeutics, MacroGenics and others.

Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Transform your understanding of the Chronic Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Myeloid Leukemia Pipeline Report
• Coverage- Global
• Chronic Myeloid Leukemia Companies- Renascience, Novartis Pharmaceuticals, AOP Orphan Pharmaceuticals GmbH, ImmunoForge, Enliven Therapeutics, MacroGenics and others.
• Chronic Myeloid Leukemia Pipeline Therapies- Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.
• Chronic Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research-Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Myeloid Leukaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Myeloid Leukaemia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name : Company Name
9. Mid Stage Products (Phase I/ II)
10. Navtemadlin: Kartos Therapeutics
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Chronic Myeloid Leukaemia Key Companies
17. Chronic Myeloid Leukaemia Key Products
18. Chronic Myeloid Leukaemia- Unmet Needs
19. Chronic Myeloid Leukaemia- Market Drivers and Barriers
20. Chronic Myeloid Leukaemia- Future Perspectives and Conclusion
21. Chronic Myeloid Leukaemia Analyst Views
22. Chronic Myeloid Leukaemia Key Companies

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.